KR940000443A - 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 - Google Patents

피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 Download PDF

Info

Publication number
KR940000443A
KR940000443A KR1019930010023A KR930010023A KR940000443A KR 940000443 A KR940000443 A KR 940000443A KR 1019930010023 A KR1019930010023 A KR 1019930010023A KR 930010023 A KR930010023 A KR 930010023A KR 940000443 A KR940000443 A KR 940000443A
Authority
KR
South Korea
Prior art keywords
pyridyl
oxadiazolecarboxamide
oxide
formula
alkyl
Prior art date
Application number
KR1019930010023A
Other languages
English (en)
Inventor
슈나핑거 칼
본 헬무트
Original Assignee
한스-게오르그 우르바흐, 랄프 물레이
카젤라 아크티엔게젤샤프트
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한스-게오르그 우르바흐, 랄프 물레이, 카젤라 아크티엔게젤샤프트 filed Critical 한스-게오르그 우르바흐, 랄프 물레이
Publication of KR940000443A publication Critical patent/KR940000443A/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/08—1,2,5-Oxadiazoles; Hydrogenated 1,2,5-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

본 발명은 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드, 이의 제조방법 및 이의 용도에 관한 것이다.
상기식에서 라디칼 R1과 R2중의 피리딜이고 다른 하나는이고, R3및 R4는 특허청구의 범위 제1항에서 정의한 바와 같다.

Description

피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (10)

  1. 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 및 이의 약리학적으로 허용되는 산부가 화합물.
    상기식에서 라디칼 R1과 R2중의 피리딜이고 다른 하나는이고, R3및 R4는 서로 독립적으로 수소, (C1-C6)-알킬, (C5-C7)-사이클로알킬, -(CH2)n-NR5R6, -(CH2)n-OR5, -(CH2)m-COOR5, -CH(Alk)-COOR5, -(CH2)m-CONR5R6,
    -(CH2)m-아릴 또는 -(CH2)m-헤테로아릴이거나 R3및 R4는 이들을 결합하는 질소원자와 함께 헤테로사이클을 형성하고; R5및 R6은 서로 독립적으로 수소, (C1-C6)-알킬, (C5-C7)-사이클로알킬, 벤질 또는 페네틸이고; Alk는 (C1-C6)-알킬이고 n은 2, 3 또는 4이고, m은 0, 1, 2 또는 3이다.
  2. 제1항에 있어서, R3및 R4가 서로 독립적으로 수소 또는 (C1-C6)-알킬임을 특징으로 하는 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드.
  3. 제1항 또는 제2항에 있어서, R3가 메틸이고 R4가 수소임을 특징으로 하는 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드.
  4. 제1항에 있어서, R3가 -(CH2)n-N(C1-C6)-알킬이고 R4가 수소임을 특징으로 하는 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드.
  5. 제1항 내지 제4항중의 어느 한 항에 있어시, 피리딜 라디칼 R1또는 R2가 피리드-3-일임을 특징으로 하는 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드.
  6. 일반식(Ⅱ)의 화합물을 산화시킴을 특징으로 하여, 제1항 내지 제5항중의 어느 한 항에 따른 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드를 제조하는 방법.
    상기식에서, R1및 R2는 제1항에서 정의한 바와 같다.
  7. 일반식(Ⅳ)의 화합물을 아민 HNR3R4(여기서 R3및 R4는 제1항에서 정의한 바와 같다)와 반응시킴을 특징으로 하여, 제1항 내지 제5항중의 어느 한 항에 따른 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드를 제조하는 방법.
    상기식에서, 라디칼 R7및 R8중의 하나는 피리딜이고 다른 하나는 반응성 산 그룹이다.
  8. 심장혈관계 질병의 치료 및 예방을 위한 제1항 내지 제5항중의 어느 한 항에 따른 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드의 용도.
  9. 직립성 기능장애의 치료를 위한 제1항 내지 제5항중의 어느 한 항에 따른 일반식(Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드를 제조하는 방법.
  10. 활성 화합물로서의 제1항 내지 제5항중의 어느 한 항에 따른 일반식 (Ⅰ)의 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 또는 이의 약리학적으로 허용되는 산 부가염을 약제학적으로 허용되는 부형제 및 첨가제 및 적합한 경우 추가의 하나 이상의 기타 약리학적 활성 물질과 함께 함유함을 특징으로 하는 약제학적 제제.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019930010023A 1992-06-05 1993-06-04 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드 KR940000443A (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE4218582A DE4218582A1 (de) 1992-06-05 1992-06-05 Pyridyl-1,2,5-oxadiazol-carbonamid-2-oxide
DEP4218582.3 1992-06-05

Publications (1)

Publication Number Publication Date
KR940000443A true KR940000443A (ko) 1994-01-03

Family

ID=6460475

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019930010023A KR940000443A (ko) 1992-06-05 1993-06-04 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드

Country Status (8)

Country Link
US (1) US5374640A (ko)
EP (1) EP0575754A1 (ko)
JP (1) JPH06172352A (ko)
KR (1) KR940000443A (ko)
CA (1) CA2097766A1 (ko)
DE (1) DE4218582A1 (ko)
HU (1) HUT65749A (ko)
ZA (1) ZA933848B (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4401150A1 (de) * 1994-01-17 1995-07-20 Cassella Ag Furazancarbonsäurederivate
US8822509B2 (en) 2006-12-29 2014-09-02 The University Of Queensland Pain-relieving compositions and uses therefor
FR2921365B1 (fr) 2007-09-21 2012-10-12 Servier Lab Nouveaux sels d'addition d'inhibiteurs d'enzyme de conversion de l'angiotensine a des acides donneurs de no, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CA2761288C (en) * 2008-07-02 2017-09-05 The University Of Queensland Pain-relieving compositions of furoxan no donors and uses thereof
WO2010019772A2 (en) * 2008-08-14 2010-02-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Oxadiazole-2-oxides as antischistosomal agents

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH498136A (de) * 1968-02-06 1970-10-31 Geigy Ag J R Verfahren zur Herstellung von neuen Furazanderivaten
CH498855A (de) * 1968-02-06 1970-11-15 Geigy Ag J R Verfahren zur Herstellung von neuen Furazanderivaten
DE3012862A1 (de) * 1980-04-02 1981-10-08 Cassella Ag, 6000 Frankfurt Substituierte 1,2,5-oxdiazol-2-oxide als pharmazeutische wirkstoffe, ihre verwendung und sie enthaltende arzneimittel
DE3047730A1 (de) * 1980-12-18 1982-07-15 Cassella Ag, 6000 Frankfurt 3,4-bis-substituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen
DE3047749A1 (de) * 1980-12-18 1982-07-22 Cassella Ag, 6000 Frankfurt 3,4-disubstituierte 1,2,5-oxdiazol-2-oxide, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen
DE3134849A1 (de) * 1981-09-03 1983-03-10 Cassella Ag, 6000 Frankfurt 1,2,5-oxadiazol-3,4-dicarbonsaeurederivate, verfahren zu ihrer herstellung, ihre verwendung und sie enthaltende pharmazeutische zubereitungen

Also Published As

Publication number Publication date
EP0575754A1 (de) 1993-12-29
JPH06172352A (ja) 1994-06-21
HUT65749A (en) 1994-07-28
HU9301651D0 (en) 1993-09-28
DE4218582A1 (de) 1993-12-09
CA2097766A1 (en) 1993-12-06
ZA933848B (en) 1993-12-28
US5374640A (en) 1994-12-20

Similar Documents

Publication Publication Date Title
IE830479L (en) Carboxyalkyl dipeptides
NO914171D0 (no) Fremgangsmaate for fremstilling av peptidforbindelser
MY130668A (en) Isothiazole derivatives useful as anticancer agents
KR970000250A (ko) 개선된 항바이러스 화합물
ATE178067T1 (de) Camptothecinderivate
CA2258548A1 (en) Phenylamino-substituted tricyclic derivatives for treatment of hyperproliferative diseases
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
KR910016931A (ko) 과콜레스테린혈증 치료제
KR890006624A (ko) 디데옥시시티딘 유도체
KR960704890A (ko) 이미다조[1,2-a] 피리딘의 알콕시알킬 카르바메이트 (ALKOXY ALKYL CARBAMATES FROM IMIDAZO [1,2-a] PYRIDINES)
RU96107392A (ru) Фотосенсибилизаторы
WO1993010742A3 (en) Chemical compounds, their preparation and use
RU94046141A (ru) Замещенные производные /арилалкоксибензил/ аминопропанамида, способы их получения, фармацевтическая композиция
NO179974C (no) Analogifremgangsmåte for fremstilling av terapeutisk aktive piperidinforbindelser
IE883048L (en) Polyamine derivatives as antineoplastic agents
KR940000443A (ko) 피리딜-1,2,5-옥사디아졸카복스아미드-2-옥사이드
KR910000607A (ko) 새로운 에스테르
FI104071B1 (fi) Analogiamenetelmä terapeuttisesti käyttökelpoisten 2,5-dihydro-2,5-diokso-1H-bents[b]atsepiinijohdannaisten valmistamiseksi
KR940000445A (ko) 페닐-1,2,5-옥사디아졸카복스아미드-2-옥사이드
NZ222045A (en) From diamides up to tetrapeptides for use as anticanvulsants
AP9801235A0 (en) Erythromycin derivatives.
GB1364284A (en) Acylaminophyrrolidinone derivatives their preparation and pharma ceutical compositions containing them
JPS5536453A (en) Novel immunosuppressive agent
RU93005013A (ru) 1-аминоспиро[изохинолин-4(1н)3-пирролидин-1,2,3,5'(2н)-тетроны] и их аналоги, способ их получения и фармацевтическая композиция
KR940021524A (ko) 1,2,5,6-테트라하이드로피리딘 유도체와 이의 제조 방법 및 치료시 이의 이용방법

Legal Events

Date Code Title Description
WITN Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid